X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The partnership aims to focus on the commercialization of Teva’s Austedo (deutetrabenazine). It is approved by the U.S. FDA in adults for the treatment of tardive dyskinesia and for the chorea associated with Huntington’s disease.
Lead Product(s): Deutetrabenazine
Therapeutic Area: Genetic Disease Product Name: Austedo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Teva Pharmaceutical Industries
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 26, 2024
Details:
Under the license agreement, Nhwa granted a license to develop, manufacture, and commercialize Olinvyk (oliceridine), an opioid medication that is used for the treatment of moderate to severe acute pain in adults, in China.
Lead Product(s): Oliceridine
Therapeutic Area: Neurology Product Name: Olinvyk
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Trevena
Deal Size: $5.5 million Upfront Cash: $2.5 million
Deal Type: Licensing Agreement May 31, 2023
Details:
Under the terms of the agreement, Complix has granted an exclusive license to Nhwa to develop, manufacture and commercialize the CPABs resulting from this collaboration in Greater China.
Lead Product(s): Alphabody Therapeutics
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Complix
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 28, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
